Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6DKJ4
UPID:
NXN_HUMAN
Alternative names:
-
Alternative UPACC:
Q6DKJ4; B4DXQ0; D3DTH2; Q3SWW6; Q6P3U6; Q7L4C6; Q9H9Q1
Background:
Nucleoredoxin, identified by the accession number Q6DKJ4, plays a pivotal role as a redox-dependent negative regulator within the Wnt signaling pathway. This regulation is crucial, as it may prevent the ubiquitination of DVL3 by the BCR(KLHL12) complex. Beyond its role in Wnt signaling, Nucleoredoxin is posited to function as a transcriptional regulator and influences the activity of protein phosphatase 2A (PP2A), underscoring its multifaceted role in cellular processes.
Therapeutic significance:
The involvement of Nucleoredoxin in Robinow syndrome, autosomal recessive 2, highlights its clinical significance. This condition, characterized by severe skeletal abnormalities, underscores the protein's potential as a therapeutic target. Understanding the role of Nucleoredoxin could open doors to potential therapeutic strategies, especially for conditions like Robinow syndrome where it plays a critical role.